Article Text

Download PDFPDF
Low complication rate during intraperitoneal therapy through a totally implanted peritoneal access port in patients with ovarian cancer
  1. A. G. NANNINGA,
  3. E.G.E. DE VRIES and
  1. Department of Medical Oncology
  2. *Gynaecology, University Hospital Groningen, The Netherlands
  1. Address for correspondence: P.H.B. Willemse, M.D., Department of Internal Medicine, University Hospital, Oostersingel 59, 9713 EZ Groningen, The Netherlands.


Fifty-three patients with histologically proven ovarian cancer were treated with intraperitoneally administered cisplatin or human recombinant interferon-alpha through a totally implanted peritoneal access port. A total of 281 treatment courses were given. No complications related to surgical implantation of the port were seen. Infectious complications, intra-abdominal problems or subcutaneous drug extravasation did not occur. In two patients the number of treatment courses was limited due to inflow obstruction. A totally implanted peritoneal access port proves to be a reliable route for the intraperitoneal treatment of patients with ovarian cancer. The strict aseptic technique we used contributes to its safety by preventing intra-abdominal infections.

  • cisplatin
  • etoposide
  • interferon-alpha
  • intraperitoneal
  • i.p catheter
  • ovarian cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.